Levetiracetam Aurovitas (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This reduces neuronal hyper‑excitability and helps prevent the rapid firing of neurons that can trigger seizures.

The dosage of Levetiracetam Aurovitas is individualized. A qualified prescriber determines the appropriate dose and infusion rate based on the patient’s clinical condition, renal function, and response to therapy.

Safety data are limited. Levetiracetam should be used during pregnancy only if the expected benefit outweighs potential risks, and breastfeeding decisions should be made after consulting a healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam has a unique mechanism targeting SV2A, offering a favorable interaction profile compared with enzyme‑inducing agents like carbamazepine or phenytoin. It is generally well tolerated, but clinicians consider individual patient factors when selecting therapy.

The product should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution before use.

Levetiracetam Aurovitas is given by intravenous infusion. The prescriber determines the infusion rate and duration, which are typically administered over a short period under clinical supervision.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome, and neuropsychiatric events such as suicidal thoughts or severe mood changes. Prompt medical attention is required if these occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications without appropriate monitoring.